- Home
- BIIB vs GFL Comparison
BIIB vs GFL Comparison
Compare BIIB & GFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- GFL
- Stock Information
- Founded
- BIIB 1978
- GFL 2007
- Country
- BIIB United States
- GFL Canada
- Employees
- BIIB N/A
- GFL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- GFL
- Sector
- BIIB Health Care
- GFL
- Exchange
- BIIB Nasdaq
- GFL Nasdaq
- Market Cap
- BIIB 19.9B
- GFL 18.1B
- IPO Year
- BIIB 1991
- GFL 2020
- Fundamental
- Price
- BIIB $124.40
- GFL $44.27
- Analyst Decision
- BIIB Buy
- GFL Strong Buy
- Analyst Count
- BIIB 27
- GFL 8
- Target Price
- BIIB $220.50
- GFL $50.13
- AVG Volume (30 Days)
- BIIB 1.8M
- GFL 2.0M
- Earning Date
- BIIB 04-23-2025
- GFL 04-30-2025
- Dividend Yield
- BIIB N/A
- GFL 0.12%
- EPS Growth
- BIIB 40.28
- GFL N/A
- EPS
- BIIB 11.18
- GFL N/A
- Revenue
- BIIB $9,675,900,000.00
- GFL $5,464,123,877.00
- Revenue This Year
- BIIB N/A
- GFL N/A
- Revenue Next Year
- BIIB N/A
- GFL $6.28
- P/E Ratio
- BIIB $11.75
- GFL N/A
- Revenue Growth
- BIIB N/A
- GFL 4.61
- 52 Week Low
- BIIB $128.51
- GFL $30.57
- 52 Week High
- BIIB $238.00
- GFL $49.35
- Technical
- Relative Strength Index (RSI)
- BIIB 32.01
- GFL 48.35
- Support Level
- BIIB $128.75
- GFL $46.94
- Resistance Level
- BIIB $144.07
- GFL $48.94
- Average True Range (ATR)
- BIIB 3.72
- GFL 1.18
- MACD
- BIIB -1.21
- GFL -0.12
- Stochastic Oscillator
- BIIB 11.38
- GFL 20.66
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.